You are here: Industry Insights > Loxo

News List

Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA contractpharma
June 25, 2019
To provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292.
AACR: Bayer posts early clinical data on follow-up to Loxo's Vitrakvi fiercebiotech
April 03, 2019
Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology.
Eli Lilly’s surprise Lartruvo failure, Loxo buy put a dent in its 2019 hopes fiercepharma
February 24, 2019
It was not so long ago, Dec. 19 to be exact, that Eli Lilly thrilled investors with 2019 revenue and earnings projections that far exceeded what analysts were expecting.
Lilly closes $8bn Loxo Oncology acquisition pharmaceutical-technology
February 19, 2019
Eli Lilly has completed the acquisition of all outstanding shares of Loxo Oncology in a deal valued at approximately $8bn, boosting its oncology portfolio with precision medicines to potentially treat genomically defined cancers.
Eli Lilly to buy Loxo Oncology for $8 billion expressbpd
January 10, 2019
The deal follows Bristol-Myers Squibb Co agreement last week to buy Celgene Corp for $74 billion, and gives Lilly access to Loxo’s portfolio of targeted medicines that treat cancers caused by rare gene mutations
Loxo Announces Breakthrough Therapy Designation from FDA for LOXO-292 americanpharmaceuticalreview
September 06, 2018
Loxo Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-292, a selective RET inhibitor
FDA grants priority review for Bayer, Loxo Oncology's larotrectinib in TRK fusion cancers firstwordpharma
May 30, 2018
Bayer announced Tuesday that the FDA granted priority review to a marketing application submitted by partner Loxo Oncology for larotrectinib to treat adult and paediatric patients with locally advanced or metastatic solid tumours harbouring a neurotrophic
Loxo Oncology Initiates Rolling Submission of NDA to FDA for Larotrectinib for the Treatment of TRK biospace
December 21, 2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively target worldpharmanews
November 20, 2017
Bayer reached an exclusive global agreement with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, CT, to develop and commercialize the larotrectinib (LOXO-101) and LOXO-195
Bayer pays $400M upfront to buy into Loxo cancer drugs fiercebiotech
November 15, 2017
Bayer has paid $400 million (€340 million) and committed to more than $1 billion more to buy into Loxo Oncology’s tropomyosin receptor kinase (TRK) inhibitor franchise.

Previous page 1 2 Next page